Pfizer’s Berobenatide Shows 15.9% Weight Loss, Eyes 10 Phase 3 Trials
PFE•Pfizer’s berobenatide achieved 15.9% non–placebo-adjusted weight loss at 32 weeks in a Phase 2b study, prompting plans for ten Phase 3 trials in 2026 and matching market-leading GLP-1 efficacy while its monthly injection showed Wegovy-like side effects in mid-stage testing. Pfizer also holds exclusive China rights to Sciwind’s ecnoglutide under a deal worth up to $495 million as Sciwind scouts global partnerships.
1. Phase 2b Study Results
Pfizer’s investigational GLP-1 receptor agonist berobenatide delivered an average 15.9% non–placebo-adjusted weight reduction at 32 weeks in its Phase 2b trial, with no plateau observed at the study midpoint, underscoring robust efficacy in chronic weight management.
2. Phase 3 Expansion Plans
Following the Phase 2b success, Pfizer outlined plans to initiate ten Phase 3 studies throughout 2026 targeting chronic weight management and obesity-related comorbidities, aiming to secure broader regulatory approvals and commercial positioning.
3. Mid-Stage Safety Profile
In a separate mid-stage trial of Pfizer’s monthly GLP-1 injection, patients experienced side effects akin to those seen with Wegovy, suggesting a comparable safety and tolerability profile as the program advances.
4. Exclusive China Rights to Ecnoglutide
Pfizer retains exclusive China commercialization rights to Sciwind’s once-weekly ecnoglutide under a deal valued at up to $495 million, while Sciwind pursues additional partnerships for markets beyond China to expand global reach.
